ImmunoCellular Therapeutics
Immunocellular Therapeutics’ work in industry-leading, next-generation cancer vaccine immunotherapies.
Launch date
Employees
Market cap
€14.2m
Enterprise valuation
€14m (Public information from Sep 2024)
Share price
$0.079 IMUC
Calabasas California (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $1.7m | Early VC | |
| N/A | $2.7m | Early VC | |
$8.1m | Debt | ||
| N/A | N/A | IPO | |
$19.9m | Grant | ||
| Total Funding | €22.1m | ||
Recent News about ImmunoCellular Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.